Literature DB >> 766620

Recurrence of membranoproliferative glomerulonephritis following kidney transplantation. Serum complement component studies.

R H McLean, H Geiger, B Burke, R Simmons, J Najarian, R L Vernier, A F Michael.   

Abstract

Sixteen patients with membranoproliferative glomerulonephritis who required kidney transplantation because of renal failure were evaluated for evidence of recurrence of the original disease by serologic and morphologic studies. Of the 12 patients with transplant tissue available for study, seven showed membranoproliferative glomerulonephritis by light morphology. Four of these seven also had hypocomplementemia, and this hypocomplementemia was characterized by decreased serum CH50, C3 beta1A or C3-C9 but norma serum C1, C4 and C2 by hemolytic assay. Immunofluorescent microscopy demonstrated more intense glomerular deposition of C3 and properdin in the hypocomplementemic patients. Ultrastructural studies demonstrated intramembranous deposits typical of dense deposit disease in one patient who also had marked hypocomplementemia. One patient who had two transplant biopsies and persistent hypocomplementemia showed progression from predominantly mesangial glomerular changes to both capillary wall and mesangial abnormalities. This study has shown a high rate of recurrence of membranoproliferative glomerulonephritis in the transplanted kidneys. A high death rate was noted in persistently hypocomplementemic patients. The serum C profile in hypcomplementemic patients who received translants was similar to that seen before transplantation, but the signficance of this finding remains unknown.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 766620     DOI: 10.1016/0002-9343(76)90534-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Pseudorejection: factors mimicking rejection in renal allograft recipients.

Authors:  A J Matas; R L Simmons; C M Kjellstrand; J S Najarian
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

2.  Antibiotic-induced modification of Bacteroides fragilis and its susceptibility to phagocytosis by human polymorphonuclear leukocytes.

Authors:  C G Gemmell; P K Peterson; D Schmeling; J Mathews; P G Quie
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

Review 3.  [Recurrence of the original disease in the transplanted kidney].

Authors:  E P Leumann; J Briner
Journal:  Klin Wochenschr       Date:  1984-04-02

4.  Dichotomy between opsonization and serum complement activation by encapsulated staphylococci.

Authors:  P K Peterson; Y Kim; B J Wilkinson; D Schmeling; A F Michael; P G Quie
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

5.  The key role of peptidoglycan in the opsonization of Staphylococcus aureus.

Authors:  P K Peterson; B J Wilkinson; Y Kim; D Schmeling; S D Douglas; P G Quie; J Verhoef
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

6.  The immunohistopathology of glomerular antigens. II. The glomerular basement membrane, actomyosin, and fibroblast surface antigens in normal, diseased, and transplanted human kidneys.

Authors:  J I Scheinman; A J Fish; A J Matas; A F Michael
Journal:  Am J Pathol       Date:  1978-01       Impact factor: 4.307

7.  Activation of complement by cell surface components of Staphylococcus aureus.

Authors:  B J Wilkinson; Y Kim; P K Peterson; P G Quie; A F Michael
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

8.  Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin.

Authors:  C G Gemmell; P K Peterson; D Schmeling; Y Kim; J Mathews; L Wannamaker; P G Quie
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

9.  Serum opsonic deficiency produced by Streptococcus pneumoniae and by capsular polysaccharide antigens.

Authors:  G S Giebink; J V Grebner; Y Kim; P G Quie
Journal:  Yale J Biol Med       Date:  1978 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.